(Q38059751)

28 August 2017

title

Plasmodium falciparum malaria vaccines: current status, pitfalls and future directions (English)

1 reference

Plasmodium falciparum malaria

28 August 2017

main subject

Plasmodium falciparum

0 references

malaria

0 references

1 reference

1 reference

Aiala Salvador

1

0 references

author name string

Rosa M Hernández

series ordinal

2

1 reference

28 August 2017

José Luis Pedraz

series ordinal

3

1 reference

28 August 2017

Manoli Igartua

series ordinal

4

1 reference

28 August 2017

publication date

1 September 2012

1 reference

Expert Review of Vaccines

28 August 2017

published in

1 reference

28 August 2017

volume

11

1 reference

28 August 2017

issue

9

1 reference

28 August 2017

page(s)

1071-1086

1 reference

New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance

28 August 2017

cites work

1 reference

Clinical malaria vaccine development

21 January 2018

1 reference

The past decade in malaria synthetic peptide vaccine clinical trials

21 January 2018

1 reference

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

21 January 2018

1 reference

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

21 January 2018

1 reference

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

21 January 2018

1 reference

Intradermal immunization of mice with radiation-attenuated sporozoites of Plasmodium yoelii induces effective protective immunity

21 January 2018

1 reference

Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity

21 January 2018

1 reference

Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites

21 January 2018

1 reference

Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection.

21 January 2018

1 reference

Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes

21 January 2018

1 reference

Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites

21 January 2018

1 reference

21 January 2018

Vaccines against malaria

1 reference

Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates

21 January 2018

1 reference

Whole parasite vaccination approaches for prevention of malaria infection

21 January 2018

1 reference

Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice.

21 January 2018

1 reference

MALVAC 2009: progress and challenges in development of whole organism malaria vaccines for endemic countries, 3-4 June 2009, Dakar, Senegal

21 January 2018

1 reference

Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model

21 January 2018

1 reference

The case for a subunit vaccine against malaria

21 January 2018

1 reference

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

21 January 2018

1 reference

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

21 January 2018

1 reference

Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against blood-stage malaria in mice.

21 January 2018

1 reference

Natural immunization against malaria: causal prophylaxis with antibiotics

21 January 2018

1 reference

Protection against a malaria challenge by sporozoite inoculation

21 January 2018

1 reference

Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study

21 January 2018

1 reference

Novel rational drug design strategies with potential to revolutionize malaria chemotherapy

21 January 2018

1 reference

Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite

21 January 2018

1 reference

Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens

21 January 2018

1 reference

A new era for innate immunity

21 January 2018

1 reference

Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates

21 January 2018

1 reference

Toll-like receptor 3 is necessary for dsRNA adjuvant effects.

21 January 2018

1 reference

A review of malaria vaccine clinical projects based on the WHO rainbow table

21 January 2018

1 reference

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

21 January 2018

1 reference

Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

21 January 2018

1 reference

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

21 January 2018

1 reference

Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein

21 January 2018

1 reference

Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy

21 January 2018

1 reference

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

21 January 2018

1 reference

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

21 January 2018

1 reference

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

21 January 2018

1 reference

The RTS,S malaria vaccine

21 January 2018

1 reference

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area.

21 January 2018

1 reference

Safety and efficacy of the RTS, S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

21 January 2018

1 reference

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

21 January 2018

1 reference

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care

21 January 2018

1 reference

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

21 January 2018

1 reference

An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines

21 January 2018

1 reference

Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres

21 January 2018

1 reference

A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.

21 January 2018

1 reference

Gamma-irradiation effects on biopharmaceutical properties of PLGA microspheres loaded with SPf66 synthetic vaccine

21 January 2018

1 reference

Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.

21 January 2018

1 reference

Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres

21 January 2018

1 reference

Immune response after oral administration of the encapsulated malaria synthetic peptide SPf66.

21 January 2018

1 reference

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

21 January 2018

1 reference

Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration.

21 January 2018

1 reference

Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate.

21 January 2018

1 reference

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus

21 January 2018

1 reference

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes

21 January 2018

1 reference

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

21 January 2018

1 reference

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

21 January 2018

1 reference

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

21 January 2018

1 reference

European Vaccine Initiative: lessons from developing malaria vaccines

21 January 2018

1 reference

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine

21 January 2018

1 reference

The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert

21 January 2018

1 reference

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

21 January 2018

1 reference

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

21 January 2018

1 reference

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

21 January 2018

1 reference

Preclinical profiling of the immunogenicity of a two-component subunit malaria vaccine candidate based on virosome technology

21 January 2018

1 reference

A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers

21 January 2018

1 reference

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial

21 January 2018

1 reference

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

21 January 2018

1 reference

Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate

21 January 2018

1 reference

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

21 January 2018

1 reference

A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children

21 January 2018

1 reference

Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36.

21 January 2018

1 reference

Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic

21 January 2018

1 reference

The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial

21 January 2018

1 reference

Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum

21 January 2018

1 reference

A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya

21 January 2018

1 reference

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

21 January 2018

1 reference

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein

21 January 2018

1 reference

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

21 January 2018

1 reference

Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

21 January 2018

1 reference

Suppression of vaccine responses by malaria: insignificant or overlooked?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.12.87

1 reference

28 August 2017

1 reference